for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Nymox Pharmaceutical Corp

NYMX.OQ

Latest Trade

2.04USD

Change

-0.08(-3.55%)

Volume

11,231

Today's Range

2.04

 - 

2.18

52 Week Range

1.25

 - 

2.85

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
2.12
Open
2.12
Volume
11,231
3M AVG Volume
2.82
Today's High
2.18
Today's Low
2.04
52 Week High
2.85
52 Week Low
1.25
Shares Out (MIL)
67.93
Market Cap (MIL)
136.79
Forward P/E
--
Dividend (Yield %)
--

Latest Developments

More

Nymox Pharmaceutical Corp Provides Update On Core Activities

Nymox Announces Expanded Marketing Plans

Nymox Announces Relocation Of Company Headquarters To Switzerland

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Nymox Pharmaceutical Corp

Nymox Pharmaceutical Corp is a Canada-based biopharmaceutical company. The Company is focused on developing its drug candidate, NX-1207, for the treatment of benign prostatic hyperplasia (BPH) and the treatment of low-grade localized prostate cancer. The Company operates through the research and development of products for the aging population segment. The Company markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. The Company also owns rights for its marketed products, its investigational drug, as well as other therapeutic and diagnostic indications. The Company also has the rights for the use of statin drugs for the treatment and prevention of Alzheimer's disease. The Company's subsidiaries include Nymox Corporation and Serex, Inc. Nymox Corporation conducts research and development, while Serex, Inc. conducts research and development, and manufacturing of NicAlert and TobacAlert.

Industry

Biotechnology & Drugs

Contact Info

St. Laurent

9900 Cavendish Blvd Suite 306

http://www.nymox.com/

Key Stats

Price To Earnings (TTM)
--
Price To Sales (TTM)
772.83
Price To Book (MRQ)
14.24
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-231.59
Return on Equity (TTM)
-169.36

Latest News

BRIEF-Nymox Announces U.S. NDA For Fexapotide For BPH

* SAYS RECENTLY HAD A PRE-NDA MEETING WITH FDA; NDA FOR FEXAPOTIDE FOR BPH WILL BE SUBMITTED LATER IN 2018 Source text for Eikon: Further company coverage:

BRIEF-Nymox Reports 5-Yr Results From Prostate Cancer Study Of Fexapotide Triflutate In 146 U.S. Men

* NYMOX REPORTS 5-YEAR RESULTS FROM PROSPECTIVE RANDOMIZED CONTROLLED PROSTATE CANCER STUDY OF FEXAPOTIDE TRIFLUTATE IN 146 U.S. MEN

BRIEF-Nymox Pharmaceutical posts qtrly loss $0.09/shr - SEC filing

* Nymox Pharmaceutical Corp qtrly loss per share $0.09 - SEC filing Source text: (http://bit.ly/2j7iBgX) Further company coverage:

BRIEF-Nymox Pharmaceutical says ‍European member states accepted MAA​ for fexapotide triflutate

* Says European member states for Nymox's MAA for fexapotide triflutate for treatment of benign prostatic hyperplasia accepted co's MAA Source text for Eikon: Further company coverage:

BRIEF-Nymox Pharmaceutical postpones September 16 AUA meeting

* Says September 16 AUA meeting in Amelia Island, Florida postponed due to hurricane disaster in Florida Source text for Eikon: Further company coverage:

BRIEF-Nymox announces private placements of $3 million

* Nymox announces private placements of $3 million Source text for Eikon: Further company coverage:

BRIEF-Nymox Pharmaceutical Corp posts qtrly loss $0.05/shr - SEC filing

* Nymox Pharmaceutical Corp says net losses were $2.7 million or $0.05 per share, for the quarter - SEC filing

BRIEF-Nymox reports additional positive data from fexapotide BPH phase 3 trial

* Nymox reports additional positive results from completed fexapotide BPH phase 3 studies showing significant early response and first-line efficacy

BRIEF-Nymox reports successful new phase 3 long-term Fexapotide repeat injection BPH trial results

* Nymox reports successful new phase 3 long-term fexapotide repeat injection bph trial results: lasting symptomatic improvement up to 6 years after single repeated treatment

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up